Structure Therapeutics Inc (GPCR)
41.75
+0.22
(+0.53%)
USD |
NASDAQ |
Sep 27, 16:00
41.65
-0.10
(-0.24%)
After-Hours: 20:00
Structure Therapeutics Cash from Operations (Quarterly): -26.39M for June 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -26.39M |
| March 31, 2024 | -34.08M |
| December 31, 2023 | -21.73M |
| September 30, 2023 | -20.56M |
| June 30, 2023 | -16.89M |
| Date | Value |
|---|---|
| March 31, 2023 | -20.31M |
| December 31, 2022 | -12.03M |
| September 30, 2022 | -10.48M |
| June 30, 2022 | -10.10M |
| March 31, 2022 | -13.52M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-34.08M
Minimum
Mar 2024
-10.10M
Maximum
Jun 2022
-18.61M
Average
-18.60M
Median
Cash from Operations (Quarterly) Benchmarks
| Viking Therapeutics Inc | -28.51M |
| Eli Lilly and Co | 1.466B |
| Novo Nordisk AS | 7.271B |
| Amgen Inc | 2.459B |
| Pfizer Inc | -1.781B |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -204.52M |
| Cash from Financing (Quarterly) | 514.70M |
| Free Cash Flow | -105.32M |
| Free Cash Flow Per Share (Quarterly) | -0.5428 |
| Free Cash Flow Yield | -5.59% |